Patents by Inventor Yoshiaki Isobe
Yoshiaki Isobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8332916Abstract: A service providing system using the biometrics identification without inputting the user ID poses the problem that the consideration of a service is erroneously claimed to the registered user not using the service due to the erroneous identification. According to this invention, the threshold of the value of the degree of similarity for user identification is set strictly for each registered biometrics information of the user in accordance with the declaration of the loss caused by the erroneous identification.Type: GrantFiled: February 26, 2009Date of Patent: December 11, 2012Assignee: Hitachi, Ltd.Inventors: Yoshiaki Isobe, Takao Murakami, Kenta Takahashi
-
Patent number: 8312521Abstract: A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat. A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.Type: GrantFiled: March 23, 2007Date of Patent: November 13, 2012Assignee: Hitachi, Ltd.Inventors: Yoshiaki Isobe, Masahiro Mimura
-
Publication number: 20120178743Abstract: An antiallergic agent for topical administration containing an adenine compound of general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: February 22, 2012Publication date: July 12, 2012Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki ISOBE, Haruo Takaku, Haruhisa Ogita, Masanori Tobe, Ayumu Kurimoto, Tetsuhiro Ogino, Hitoshi Fujita
-
Patent number: 8148371Abstract: A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: June 3, 2010Date of Patent: April 3, 2012Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Haruo Takaku, Haruhisa Ogita, Masanori Tobe, Ayumu Kurimoto, Tetsuhiro Ogino, Hitoshi Fujita
-
Publication number: 20110306610Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.Type: ApplicationFiled: July 20, 2011Publication date: December 15, 2011Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Ayumu KURIMOTO, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
-
Patent number: 8079061Abstract: Inputted information (such as biometric information) is compared to template information (including correlation or authentication) and the result is recorded as log information. According to log information for each of the types of the inputted information (such as information specifying the user who has inputted it and the template), analysis is executed for the inputted information for each of the types. This analysis includes the following aspects. That is, the following states are detected and an alarm is outputted for the accuracy of the corresponding type: when the ratio of negative comparison results (correlation failures) not smaller than a predetermined value is detected within a predetermined period of time; and when a negative result is detected within a predetermined time before an affirmative comparison result is obtained.Type: GrantFiled: December 3, 2007Date of Patent: December 13, 2011Assignee: Hitachi, Ltd.Inventors: Kazuhiko Taniguchi, Yoshiaki Isobe, Nariyasu Hamada, Hiroyuki Shimizu
-
Patent number: 8044056Abstract: A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.Type: GrantFiled: March 19, 2008Date of Patent: October 25, 2011Assignees: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AktiebolagInventors: Yoshiaki Isobe, Tomoaki Nakamura
-
Patent number: 8012964Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.Type: GrantFiled: March 24, 2005Date of Patent: September 6, 2011Assignees: Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca AktiebolagInventors: Ayumu Kurimoto, Yoshiaki Isobe, Stephen Brough, Hiroki Wada, Roger Bonnert, Thomas McInally
-
Publication number: 20110185176Abstract: At a registration time, a feature data array for registration is generated from biometric information acquired by a client, and a position correction template and a comparison template obtained by converting the feature data array for registration are registered in a server. At an authentication time, a feature data array for authentication is generated from biometric information acquired by the client, and converted feature data for position correction obtained by converting the feature data array for authentication is transmitted to the server. The server detects a position correction amount of the feature data array for authentication relative to the feature data array for registration using the position correction template and the converted feature data for position correction, and transmits the position correction amount to the client.Type: ApplicationFiled: August 21, 2009Publication date: July 28, 2011Inventors: Kenta Takahashi, Shinji Hirata, Yoshiaki Isobe
-
Publication number: 20110136801Abstract: The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: December 2, 2010Publication date: June 9, 2011Applicants: Dainippon Sumitomo Pharma Co. Ltd., AstraZeneca ABInventors: Yoshiaki Isobe, Mai Kasai, Tomoaki Nakamura, Shingo Tojo, Hirotaka Kurebayashi
-
Publication number: 20110138187Abstract: In additional enrollment of a template in a biometric authentication system, the template is automatically enrolled on the basis of a plurality of authentication results to assure a user's convenience and security. A post-migration authentication server receives a first template and a second template from a post-migration authentication terminal, performs authentication on the basis of the comparison result between the received first template and the user's preliminarily first enrolled template, and provisionally enrolls the first template and the second template. It repeats the reception, authentication, and provisional enrollment and calculates a match probability from a plurality of comparison results of the provisionally first enrolled templates, determines whether or not to store a second enrolled template on the basis of the match probability, and automatically enrolls the second template in the post-migration authentication server.Type: ApplicationFiled: September 1, 2010Publication date: June 9, 2011Applicant: Hitachi, Ltd.Inventors: Yosuke KAGA, Osamu TAKATA, Yoshiaki ISOBE, Kenta TAKAHASHI, Takao MURAKAMI
-
Publication number: 20110028715Abstract: A novel adenine compound represented by the formula (1): wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1 and L2 each independently represents straightened or branched alkylene, etc.; R1 represents halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted aryl, or (un)substituted heteroaryl; R2 and R3 each independently represents hydrogen, or (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted saturated heterocycle, (un)substituted aryl, or (un)substituted heteroaryl, or R2 combines together with L2 or R3 to form (un)substituted 4- to 8-membered nitrogen-containing saturated heterocycle; X is oxygen, sulfur, SO, SO2, NR7, NR7CO wherein R7 is hydrogen or alkyl, or a single bond; provided that X is a single bond when R1 is halogen, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 14, 2010Publication date: February 3, 2011Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AktiebolagInventors: Yoshiaki ISOBE, Tomoaki NAKAMURA
-
Publication number: 20100298364Abstract: The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: May 20, 2010Publication date: November 25, 2010Applicants: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Nicholas James BENNETT, Thomas McInally, Austen Pimm, Stephen Thom, Yoshiaki Isobe
-
Publication number: 20100256118Abstract: A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 3, 2010Publication date: October 7, 2010Applicant: Dainippon Sumitomo Pharma Co.,Ltd.Inventors: Yoshiaki ISOBE, Haruo Takaku, Haruhisa Ogita, Masanori Tobe, Ayumu Kurimoto, Tetsuhiro Ogino, Hitoshi Fujita
-
Patent number: 7754728Abstract: A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: September 26, 2003Date of Patent: July 13, 2010Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Haruo Takaku, Haruhisa Ogita, Masanori Tobe, Ayumu Kurimoto, Tetsuhiro Ogino, Hitoshi Fujita
-
Publication number: 20100099870Abstract: A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.Type: ApplicationFiled: March 19, 2008Publication date: April 22, 2010Applicants: Dainippon Sumitomo Phama Co., Ltd, AstraZeneca AktiebolagInventors: Yoshiaki Isobe, Tomoaki Nakamura
-
Publication number: 20100093998Abstract: A novel adenine compound represented by the formula (1): wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1 and L2 each independently represents straighted or branched alkylene, etc.; R1 represents halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted aryl, or (un)substituted heteroaryl; R2 and R3 each independently represents hydrogen, or (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted saturated heterocycle, (un)substituted aryl, or (un)substituted heteroaryl, or R2 combines together with L2 or R3 to form (un)substituted 4- to 8-membered nitrogen-containing saturated heterocycle; X is oxygen, sulfur, SO, SO2, NR7, NR7CO wherein R7 is hydrogen or alkyl, or a single bond; provided that X is a single bond when R1 is halogen, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 19, 2008Publication date: April 15, 2010Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AktiebolagInventors: Yoshiaki Isobe, Tomoaki Nakamura
-
Publication number: 20100011423Abstract: A service providing system using the biometrics identification without inputting the user ID poses the problem that the consideration of a service is erroneously claimed to the registered user not using the service due to the erroneous identification. According to this invention, the threshold of the value of the degree of similarity for user identification is set strictly for each registered biometrics information of the user in accordance with the declaration of the loss caused by the erroneous identification.Type: ApplicationFiled: February 26, 2009Publication date: January 14, 2010Inventors: Yoshiaki Isobe, Takao Murakami, Kenta Takahashi
-
Publication number: 20090307764Abstract: A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat. A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.Type: ApplicationFiled: March 23, 2007Publication date: December 10, 2009Inventors: Yoshiaki Isobe, Masahiro Mimura
-
Publication number: 20090192153Abstract: An adenine compound or its pharmaceutically acceptable salt as a medicament as shown following formula (1): wherein R1 is optionally substituted alkyl group, etc., X is oxygen atom, etc., A is 4 to 8 membered optionally substituted saturated or unsaturated heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom, L1 and L2 are independently straight or branched chain alkylene, or a single bond, R2 is optionally substituted alkyl group, etc.Type: ApplicationFiled: September 21, 2006Publication date: July 30, 2009Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A corporation of SwedenInventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Ayumu Kurimoto, Yoshiaki Isobe, Haruhisa Ogita, Ian Millichip, Thomas Mcinally, Roger Bonnert